marketsgonewild

Innovative, Articulate, and Easy to Follow: The Premiere Synthetic Biology Event on Track for Record Attendance in 2023

SynBioBeta Global Synthetic Biology Conference Registration Open SynBioBeta announces event dates, keynotes, sponsors, and location SAN FRANCISCO, Feb. 01, 2023 (GLOBE NEWSWIRE) — Anticipation and excitement builds for the 2023 SynBioBeta Global Synthetic Biology Conference with global innovation network SynBioBeta announcing today event dates, keynotes, sponsors, and conference location. Set to be the largest synthetic…

Read More

Revolutionizing Proxy Voting: Iconik Teams Up with Green Alpha Investments for Impactful Change

Embracing the Future of Investment: iconik’s Revolutionary Proxy Voting Platform Empowering Investors with Personalized Voting Technology The financial world is ever-evolving, with technological advancements paving the way for more personalized and impactful investment strategies. iconik’s recent partnership with Green Alpha Investments marks a significant milestone in this journey towards empowering investors with customizable shareholder voting…

Read More

Unleashing the Power of Brand Engagement: DemandLab Makes the 2023 Chief Marketer 200 Exclusive List!

Welcome to DemandLab: A Leader in B2B Martech Global B2B Digital Marketing Agency Included on List of Top 200 Brand Engagement and Experience Agencies PHILADELPHIA, Jan. 31, 2023 (GLOBE NEWSWIRE) — For the second year in a row, Global enterprise B2B digital marketing agency and marketing-led customer experience innovator DemandLab has been named to the…

Read More

Breaking News: Dupixent (Dupilumab) Receives CHMP Recommendation for Expanded EU Approval to Treat Severe Atopic Dermatitis in Children as Young as Six Months Old

Dupixent® (dupilumab) Recommended for Expanded EU Approval by the CHMP Introduction Exciting news in the world of dermatology as Dupixent is recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis. If approved, Dupixent would be the first and only targeted medicine in the…

Read More